Table 2:
Treatment characteristics for all patients (N=219), patients with age < 45 years (n=111) and patients with age ≥ 45 years (n=108).
| Characteristic | All n, % |
Age < 45 years n, % |
Age ≥ 45 years n, % |
P |
|---|---|---|---|---|
| Treatment sequence | 0.55 | |||
| CRT, TME | 6 (2.7) | 4 (3.6) | 2 (1.9) | |
| CRT, TME, chemotherapy | 196 (89.5) | 95 (85.6) | 101 (93.5) | |
| CRT, chemotherapy, TME | 1 (0.5) | 1 (0.9) | 0 (0.0) | |
| CRT, chemotherapy, TME, chemotherapy | 3 (1.4) | 2 (1.8) | 1 (0.9) | |
| Chemotherapy, CRT, TME | 1 (0.5) | 1 (0.9) | 0 (0.0) | |
| Chemotherapy, CRT, TME, chemotherapy | 11 (5.0) | 7 (6.3) | 4 (3.7) | |
| Chemotherapy, CRT, chemotherapy, TME, chemotherapy | 1 (0.5) | 1 (0.9) | 0 (0.0) | |
| Median radiotherapy dose [IQR], Gy | 50.4 [50.4–50.4] | 50.4 [50.4–50.4] | 50.4 [50.4–50.4] | 0.31 |
| Concurrent chemotherapy | 0.25 | |||
| Capecitabine | 178 (81.3) | 87 (78.4) | 91 (84.3) | |
| 5-FU | 24 (11.0) | 16 (14.4) | 8 (7.4) | |
| Capecitabine with other agents | 17 (7.8) | 8 (7.2) | 9 (8.3) | |
| Post-operative chemotherapy | 0.056 | |||
| FOLFOX | 115 (52.5) | 59 (53.2) | 56 (51.9) | |
| Capecitabine | 39 (17.8) | 12 (10.8) | 27 (25.0) | |
| XELOX | 26 (11.9) | 15 (13.5) | 11 (10.2) | |
| 5-FU, leucovorin, with or without other agents | 21 (9.6) | 14 (12.6) | 7 (6.5) | |
| Other | 10 (4.6) | 5 (4.5) | 5 (4.6) | |
| None | 8 (3.7) | 6 (5.4) | 2 (1.9) | |
| Surgery | 0.86 | |||
| Low anterior resection | 101 (46.1) | 52 (46.8) | 49 (45.4) | |
| Proctectomy with coloanal anastomosis | 73 (33.3) | 36 (32.4) | 37 (34.3) | |
| Abdominoperineal resection | 39 (17.8) | 19 (17.1) | 20 (18.5) | |
| Pelvic exenteration | 6 (2.7) | 4 (3.6) | 2 (1.9) |
Abbreviations: 5-FU, 5-fluorouracil; CRT, chemoradiotherapy; FOLFOX, folinic acid, fluorouracil, and oxaliplatin; Gy, gray; IQR, interquartile range; TME, total mesorectal excision; XELOX, capecitabine and oxaliplatin